Skip to content

ADIAL PHARMACEUTICALS, INC.

ADIL

CIK 0001513525

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$8M
+39.6% YoY Q1 May 2026
EPS Diluted (TTM)
−$10.26
+82.5% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$7.19M
Q1 May 2026
Cash
$5.88M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
2.14M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings